Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 12/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 11/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160469 | 0.97 | OPRL1 (0.47) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL4163269 | 0.95 | AKR1B1 (0.49) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL4168465 | 0.86 | OPRL1 (0.44) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL4165436 | 0.86 | AKR1B1 (0.47) | AKR1B1AKR1A1OPRL1SCN9ACRHR1 | |
| SCHEMBL4160240 | 0.83 | OPRL1 (0.51) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL4164608 | 0.83 | AKR1B1 (0.46) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL4169761 | 0.83 | OPRL1 (0.48) | AKR1B1OPRL1OPRM1OPRK1SCN9A | |
| SCHEMBL4179015 | 0.83 | AKR1B1 (0.43) | AKR1B1AKR1A1SCN9A | |
| SCHEMBL4177865 | 0.81 | OPRL1 (0.41) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL4156540 | 0.80 | OPRL1 (0.56) | AKR1B1AKR1A1OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | AKR1B1 344/4885AKR1A1 310/4885OPRL1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.